Tetraphase Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares in its Initial Public Offering
WATERTOWN, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the
underwriters for its initial public offering have exercised their
over-allotment option and purchased an additional 797,792 shares in the
offering. The sale of the additional shares, together with the shares
sold at the initial closing of the offering, brings the total number of
shares sold in the offering to 11,512,078 resulting in aggregate
proceeds of $80.6 million, before underwriting discounts, commissions
and expenses. Tetraphase's common stock is listed on the NASDAQ Global
Market under the symbol "TTPH." All of the shares in the offering were
offered by Tetraphase Pharmaceuticals.
Barclays and BMO Capital Markets are acting as joint book-running
managers. Stifel, JMP Securities and Needham & Company are acting as
co-managers for the offering.
A registration statement relating to these securities has been declared
effective by the Securities and Exchange Commission (SEC) on March 19,
2013. The offering is being made only by means of a prospectus. A copy
of the final prospectus relating to these securities has been filed with
the SEC and may be obtained from: Barclays Capital Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717,
by calling (888) 603-5847, or by emailing firstname.lastname@example.org,
or by calling BMO Capital Markets at (800) 414-3627, or by emailing email@example.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its
proprietary chemistry technology to create novel antibiotics for serious
and life-threatening multi-drug resistant infections. Tetraphase's lead
product candidate, eravacycline, is a fully synthetic tetracycline
derivative being developed as a broad-spectrum intravenous and oral
antibiotic for use as a first-line empiric monotherapy for the treatment
of multi-drug resistant infections, including multi-drug resistant
Senior Vice President & CFO
Sam Brown Inc.
Source: Tetraphase Pharmaceuticals, Inc.
News Provided by Acquire Media
Close window | Back to top